Transplantation is the most important platform for achieving long-term disease-free survival — and, for many hematologic diseases, cure. GHG delivers personalized transplant therapy with whole-process risk control: from pre-transplant evaluation and donor matching to conditioning, infusion, complication management and multi-year follow-up.
Success depends on depth of disease control, donor selection, conditioning intensity, infection control, GVHD management and long-term relapse monitoring.
Disease status, MRD, organ function, infection risk, prior treatment and physical status assessment.
Select an appropriate donor; collect stem cells and complete quality and safety assessment.
Chemotherapy / radiotherapy / immunosuppression to eliminate residual disease and create conditions for engraftment.
Healthy hematopoietic stem cells are infused, initiating hematopoiesis and immune reconstitution.
Monitoring and supportive care for engraftment, infection, bleeding, organ toxicity and GVHD.
Long-term management of MRD, chimerism, immune reconstitution, infection, GVHD and relapse.
During the neutropenic phase after conditioning, patients recover inside positive-pressure laminar-flow rooms with continuous air filtration, dedicated staff and strict infection-control protocols — the foundation for safe engraftment.
GHG's HSCT centres in Beijing, Shanghai and Guangzhou have pioneered multiple innovative transplant strategies and performed over 4,000 transplants — most in patients with relapsed or refractory disease. One-year overall survival exceeds 79%, establishing GHG as one of the most effective transplant centres in China.
The core clinical challenge — balancing the graft-versus-leukemia (GVL) effect against graft-versus-host disease (GVHD) — is met with personalized conditioning, donor selection, T-cell depletion/modulation, infection prevention and dynamic monitoring of chimerism and MRD.
Eight signature transplant programmes with world-leading published outcomes.
Rapid disease control before transplant, deeper MRD clearance, dual immunologic attack and lower relapse risk. For R/R B-ALL patients achieving MRD-negativity after CAR-T, 1-year OS 84.8% and DFS 77.8%. For R/R T-ALL/LBL, 2-year OS 54.4% and DFS 51.0%.
Dual-mechanism tumor clearance and prolonged remission. For R/R B-cell lymphoma: 1/2/3-year PFS 76.6% / 72.3% / 64.7%; OS 91.5% / 73.9% / 66.0%. For R/R CNS lymphoma, PFS not reached vs. 31.2 months control.
GHG achieved the world's first GVHD-free / TM-free survival (GTFS) rate above 80% with TDH for thalassemia — 97.1% successful engraftment, OS 96.5%, TFS 94.3%. Triple protocol (CAR-T + UCB + TDH) reaches OS and DFS of 96% for R/R ALL across all age groups.
For patients undergoing a second transplant: 1-year DFS 72.5%, OS 80.6%, non-relapse mortality only 2.3% — significantly exceeding international benchmarks.
Age barriers pushed to 76 years old through personalized risk assessment, reduced-intensity conditioning and diverse donor options.
Salvage HSCT represents 85% of all transplant cases at GHG's single centre, achieving a success rate of up to 50% — the only potentially curative option for long-term disease-free survival.
Modified ATG-containing conditioning and individualized strategy: 2-year OS approaches 70%, versus historical 20–30%.
Prof. Chun WANG's team achieved 5-year survival improvement and a 60% cure rate with modified conditioning and individualized strategies.
At GHG, stem-cell transplantation benefits both cancerous and non-cancerous diseases.
Paediatric and adult patients recover with a dedicated multidisciplinary team — hematologists, transplant coordinators, infection-control specialists and psychologists — supporting the whole family through engraftment, discharge and years of monitoring.
Free Case Feasibility Assessment
Based in Hong Kong and serving international patients, Privilege Medical bridges you to leading Class 3A and JCI-accredited hospitals in mainland China. We do not provide medical care directly — we coordinate specialist matching, medical visa support and on-the-ground concierge from your first enquiry to post-treatment follow-up.
Complete the form below. Our coordination team responds within 1–2 business days with a complimentary assessment covering clinical feasibility, specialist matching and an indicative admission timeline.
Privacy Notice
Privilege Medical is a Hong Kong–based medical concierge and does not provide clinical care. Personal data and medical information you submit are collected, held and used strictly for the purposes of case assessment, specialist matching and coordination of medical services in mainland China, in accordance with the Personal Data (Privacy) Ordinance (Cap. 486) of Hong Kong.
Your data may be transferred to our partner hospitals, treating clinicians and authorised service providers (including translators and travel coordinators), some of whom are located outside Hong Kong. We take reasonable steps to keep your information confidential and secure, and we do not sell your data to any third party.
You have the right, under the PDPO, to request access to and correction of the personal data we hold about you, and to withdraw consent at any time by writing to service@privilegemedical.com. Information submitted via this form is not encrypted end-to-end; please avoid including highly sensitive identifiers (e.g. ID numbers) in the free-text fields.